Bioavailability of Apixaban Crushed Tablet

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the bioavailability of apixaban crushed tablets suspended in water or mixed with applesauce is similar to the bioavailability of apixaban whole tablets administered orally.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034591

Healthy Subjects

COMPLETED PHASE1

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects

NCT02034565

Healthy Volunteers

COMPLETED PHASE1

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

NCT02034578

Healthy Volunteers

COMPLETED PHASE1

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

NCT03509883

Healthy Volunteers

COMPLETED PHASE1

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641

Thrombosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will investigate the bioavailability of apixaban administered as crushed tablets suspended in water and as crushed tablets mixed with applesauce compared with that of whole tablets. The study results may allow enhancement of the apixaban label to include alternative methods of apixaban administration, which may be of benefit to patients who have difficulty swallowing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apixaban, 10 mg (whole tablets)

Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)

Group Type EXPERIMENTAL

Apixaban

Intervention Type DRUG

Apixaban, 10 mg (crushed and suspended in water)

Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water

Group Type EXPERIMENTAL

Apixaban

Intervention Type DRUG

Apixaban, 10 mg (crushed and mixed with applesauce)

Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce

Group Type EXPERIMENTAL

Apixaban

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apixaban

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Eliquis®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy participants as determined by no clinically significant deviation from normal in findings of medical history, physical examination, electrocardiograms, vital signs, and clinical laboratory tests.
* Women of childbearing potential allowed. Must be following highly effective methods of contraception

Exclusion Criteria

* Any significant acute or chronic medical illness
* History of significant head injury within the last 2 years, including individuals with base of skull fractures
* Any major surgery within 4 weeks of study drug administration or anticipated within 2 weeks after completion of the study
* Any gastrointestinal (GI) surgery or GI disease that could impact absorption of study drug
* History of Gilbert's Syndrome
* Inability to tolerate oral medication
* Inability to be venipunctured and/or tolerate venous access
* Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study drug administration
* Any laboratory test results outside of the range of normal, confirmed by repeat results of:

* Platelet count \<150,000 cells/µL
* Activated partial thromboplastin time \>upper limit of normal (ULN)
* International normalized ratio \>ULN
* Alanine aminotransferase \>ULN
* Aspartate aminotransferase \>ULN
* Total bilirubin \>ULN
* Serum creatinine ≥1.5 mg/dL
* Hemoglobin \<lower limit of normal (LLN)
* Hematocrit \<LLN

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes